癌症中的IGF-1R向 - 亚细胞局部化是否重要?
Upendra K Soni1, Liam Jenny1, Rashmi S Hegde2
1Division of Developmental Biology, Department of Pediatrics, Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, OH, USA.
Journal of experimental & clinical cancer research : CR
|October 20, 2023
概括
针对胰岛素样生长因子受体 (IGF-1R) 的向癌症疗法由于耐药性和毒性而失败. IGF-1R的亚细胞局部化可能是未来治疗策略的预测生物标志物.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 胰岛素类生长因子受体 (IGF-1R) 是癌症治疗的关键标.
- 之前的IGF-1R向药物面临着耐药性,毒性和缺乏患者分层的挑战.
- 尽管临床试验失败了,但人们对IGF-1R疗法有了新的兴趣.
研究的目的:
- 审查IGF-1R向药物开发的历史.
- 探索IGF-1R亚细胞局部化作为预测生物标志物的潜力.
- 调查IGF-1R局部化和治疗敏感性之间的相关性.
主要方法:
- 审查临床试验数据和科学文献.
- 对抗性和毒性机制的分析.
- 探索基于生物标志物驱动的患者分层.
主要成果:
- 早期的临床试验强调了IGF-1R抑制剂的耐药性和毒性问题.
- IGF-1R的亚细胞局部化成为潜在的预测生物标志物.
- 缺乏患者分层限制了先前治疗策略的成功.
结论:
- 下一代IGF-1R疗法需要预测生物标志物来选择患者.
- IGF-1R的亚细胞局部化显示为指导治疗决策的前景.
- 结合IGF-1R抑制剂的组合疗法可能会从这种生物标志物方法中受益.
关键词:
生物标志物 生物标志物组合疗法是一种联合疗法.在IGF-1RR中,IGF-1R是最常见的.核IGF-1R是一种核IGF-1R.复制应激是复制应激的一种.肉瘤肉瘤是一种肉瘤.治疗方法 治疗方法癌症 癌症 癌症 癌症 癌症更多相关视频
相关概念视频
Mitogens and the Cell Cycle
6.5K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.5K
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
Receptor Downregulation in MVBs
2.1K
Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
2.1K
Abnormal Proliferation
4.5K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
PI3K/mTOR/AKT Signaling Pathway
3.6K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.6K


